Study of the effect of the exhale through the nose method by Inhaled corticosteroid and Long Acting Beta2 Agonist (ICS / LABA) combination drug in patients with asthma merger sinusitis

Study of the effect of the exhale through the nose method by Inhaled corticosteroid and Long Acting Beta2 Agonist (ICS / LABA) combination drug in patients with asthma merger sinusitis - Study of the effect of the exhale through the nose method by ICS / LABA combination drug in patients with asthma merger sinusitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021822

Enrollment

Registered

2016-05-10

Start date

2016-05-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma Sinusitis Eosinophilic sinusitis

Interventions

exhale through the nose method Fluticasone propionate / formoterol fumarate combination(:FFC) drug Inhaled by exhale through the nose method twice a day 2 times per once. Between three months. Inhal

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: There are nasal symptoms in a person who has been diagnosed with asthma by a respiratory physician, who the existence of sinusitis in the paranasal sinuses CT has been confirmed. Who can stop using a combination banned drug during a given period and test period of the previous inspection.

Exclusion criteria

Exclusion criteria: 1)Those who in this study implementation period is scheduled to surgery for sinusitis 2)A person who has a history that is considered to have an impact on the evaluation of the study (drug abuse, dependence, alcohol abuse, dependence, digestive, heart, liver, lung, eye, blood diseases, etc.) 3)person of corticosteroids, while taking cromolyn sodium (oral oral medicine, nasal drops is not allowed) 4)those who are taking anti-histamines 5)Those who are receiving immunotherapy, including desensitization therapy 6)pregnant women, breast-feeding women 7)current smokers, non smoking duration a person of less than one year 8)Those who can not properly enforce the respiratory function test 9)Other, who is determined to be ineligible as a subject of the present study than test doctor

Design outcomes

Primary

Measure	Time frame
Evaluation of the Lund-Mackey staging system CT scoring three months after the intervention	—

Secondary

Measure	Time frame
Rhinosinusitis endoscopic findings, eosinophils in nasal discharge, respiratory function tests, FeNO, IL-4, IL-5, IL-10, INF-gamma, ECP, peripheral blood eosinophil count, non-specific IgE quantitation, SNOT-22 (Sino-Nasal Outcome Test-22), ACT (Asthma Control Test)	—

Countries

Japan

Contacts

Public ContactHIRANO KOJIRO

Showa University Koto Toyosu Hospital Department of Otorhinolaryngology

hirano.yasu@hotmail.co.jp03-6204-6000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026